This study involves a number of different medications.
Relatlimab is an experimental immunotherapy drug that works by blocking a molecule called LAG-3. This allows the immune system to more effectively target and destroy cancer cells. The drug is also called BMS-986016 in some clinical trials.
The other drug in is this study is called Nivolumab (Opdivo®); an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. This drug performs a similar role to relatlimab, but does so by targetting a molecule called PD-1.
Patients enrolling on this study will be randomly assigned to one of two groups:
- Relatlimab alone
- Relatlimab + Nivolumab
The researchers will monitor the safety and effectiveness of each treatment regimen for up to 3 years after completion
Different doses and administration schedules will be used to determine the optimal dosage of these drugs.
- All subtypes eligible
- Cancer has spread or cannot be removed by surgery
- No prior treatment with immunotherapy
- (i.e. Nivolumab (Opdivo®) or Pembrolizumab (Keytruda®))
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorDr Marcus Butler||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreHôpital Hôtel-Dieu de Québec||Principal InvestigatorDr Joel Claveau||LocationQuébec, QC||Trial StatusRecruiting|